Analysis
GLP-1 DTC Telehealth — SWOT Analysis
A SWOT analysis of the direct-to-consumer telehealth model for GLP-1 drugs, built on 528 clones open to GLP-1: five strengths, weaknesses, opportunities and threats each, with the consumer evidence behind them.
- Who was asked
- US consumer clones open to GLP-1, 528 clones
- When
- February 2026
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person, run on the Brox platform.
The full report GLP-1 DTC Telehealth — SWOT Analysis Open the report
Section 01: What the study found
Section 02: Where this sits
Ask this of your own customers: humans@brox.ai
More in Pharma & HCP
All in Pharma & HCP-
Veridian Oncology, an Invented Biotech: M&A Stress Test
18% peak-share assumption after the patient evidence, down from management's 30% (base 958)
Read -
肥満・糖尿病治療薬GLP-1に対する意識調査の詳細分析 | GLP-1 Perception Deep Dive (JP)
900 clones asked how likely they would be to try a GLP-1 at four monthly price points; even free barely moved the needle (base 900)
Read -
GLP-1 Derin Algı Analizi | GLP-1 Perception Deep Dive (TR)
900 clones asked how likely they would be to try a GLP-1 at four monthly price points; even free barely moved the needle (base 900)
Read